Authors

18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19

64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer

The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study

Kira MacDougall, MD, and co-investigators, research the importance of peripheral biomarkers in patients with advanced non–small cell lung cancer who are treated with pembrolizumab.

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?

Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship

The lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.

60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations

Efficacy and Safety of Zolbetuximab in Gastric Cancer

Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.

60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations

Decisional Capacity Determination in Patients With Cancer

Experts discuss the process of assessing decision-making capacity in patients with cancer.

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast

Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017

Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.

How Radiologists Could Use Cryoablation to Put Cancer Pain on Ice

J. David Prologo, MD, FSIR, ABOM-D, an interventional radiologist at Emory Healthcare, details how cryoablation can be used by radiologists to manage pain in patients with cancer.

Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review

Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

Efficacy and Safety of Zolbetuximab in Gastric Cancer

Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.

Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon Cancer

This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.

Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US

Ibrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.

Outcomes of Patients on Transplant Waiting Lists: Q&A with Dr. Giancarlo Fatobene

The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer

Disitamab vedotin, toripalimab, and trastuzumab demonstrated superior response rates and efficacy in HER2-overexpressing metastatic gastric cancers.

23 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2-Negative (HER2) Breast Cancer (BC)

The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral Center

COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.

Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?

The level of scientific evidence in National Comprehensive Cancer Network guidelines for malignant hematological conditions haven’t been recently investigated. Herein, investigators describe the distribution of categories of evidence and consensus among the 10 most common hematologic malignancies with regard to recommendations for staging, initial and salvage therapy, and surveillance.

63 Choice Architecture Bias in Genetic Counseling of Breast Cancer Patients